Straits Times Index
3,336.59 +13.21 (+0.40%) Nikkei
38,487.90 +433.77 (+1.14%) Hang Seng
18,079.61 -150.58 (-0.83%) FTSE 100
8,275.38 +44.33 (+0.54%) Bitcoin USD
68,038.64 +403.09 (+0.60%) CMC Crypto 200
1,430.16 +1.59 (+0.11%)
MXCT Oct 2024 2.500 call
| Previous close | 1.4000 |
| Open | 1.4500 |
| Bid | 1.0000 |
| Ask | 5.0000 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 1.4000 - 1.4500 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
GlobeNewswireMaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th at 2:40 pm CT. A live and archived webcast of
Simply Wall St.With 64% ownership of the shares, MaxCyte, Inc. (LON:MXCT) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies MaxCyte's stock price is sensitive to their trading...
- GlobeNewswire
MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells.ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell
